Hints and tips:
...He has moved to disentangle Novartis from part of the asset swap deal struck four years ago with GSK: a multi-pronged agreement that his predecessor, Joe Jimenez, had identified to the FT in a valedictory...
...As R&D boss, he can claim credit for Novartis’s well-stocked pipeline of drugs....
...I think having Vas . . . will put the science more at the core, which is how the company was initially conceived . . . so I think it’s a bit of an R&D takeover.”...
...The company would have “to execute extremely well in R&D” to convince investors that “the pipeline can support longer term growth”, wrote Alistair Campbell at Berenberg in a note....
...Hilary Thomas, chief medical adviser to KPMG, the professional services firm, points out Ms Walmsley is not the first to secure a seat at pharma’s top table from a consumer background: Joe Jimenez, who runs...
...“China’s going to become very important in R&D in this industry, not in the short term but over the long term,” he said....
...The Orlando Sentinel said he moved to Florida from Puerto Rico and had previously worked for Toys R Us. Luis S....
...“R&D is not a quarterly report activity — it is something that comes in waves,” he said. “There are breakthroughs in understanding and that leads to new medicines.”...
...The aim, he said, was for back-office savings to help keep total spending flat over the next five years even as the group invested heavily in R&D and product launches....
...In conjunction with the freight railways, the government launched a R$42bn package of motorway concessions to be auctioned within a year....
...Cuts in R&D spending have left the industry more dependent on young and nimble biotech companies to come up with new drugs....
...Joe Jimenez, Novartis chief executive, says those days are coming to an end. “The industry has to shift over time from what is today a transactional approach to an outcomes-based approach.”...
...Average R&D intensity — the percentage of revenue invested in R&D — among drugmakers is almost 15 per cent, according to research by Deloitte, commissioned by Janssen, the pharmaceuticals arm of Johnson...
...Instead, Mr Vasella pushed aside his close colleague and named Joe Jimenez as chief executive. Mr Reinhardt moved on to the healthcare arm of Bayer in his native Germany....
...“There are assets embedded in most companies that are worth more to others,” says Joe Jimenez, chief executive of Novartis....
...“Manaus will become much more known in the world because of the World Cup,” says Arthur Virgilio Neto, the mayor....
...there is a lot of money, and governments are trying to attract R&D at the same time as there is a squeeze in Europe....
...He pledged that Novartis would remain firmly committed to developing innovative new drugs, with R&D investment at the company ahead of the industry average at 20 per cent of sales....
...Having come to pharmaceuticals from outside the sector, his core message is that the new conditions oblige drugs companies to review spending and strategy, and to squeeze out unnecessary costs to maintain R&...
...Charles Mills of Credit Suisse agrees: “The drug industry has very strong R&D but the food companies have the marketing skills.”...
...“Today the Lula government ended,” said Arthur Virgilio, Senate leader of the opposition social democratic PSDB party....
International Edition